87 related articles for article (PubMed ID: 728326)
1. Platelet aggregation and chlorpromazine therapy.
Boullin DJ; Know JM; Peters JR; Orr MW; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1978 Dec; 6(6):538-40. PubMed ID: 728326
[No Abstract] [Full Text] [Related]
2. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.
Boullin DJ; Woods HF; Grimes RP; Grahame-Smith DG
Br J Clin Pharmacol; 1975 Feb; 2(1):29-35. PubMed ID: 791316
[TBL] [Abstract][Full Text] [Related]
3. Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
Youdim MB; Hefez A; Oppenheim B
Br J Clin Pharmacol; 1981 Oct; 12(4):535-42. PubMed ID: 7295487
[TBL] [Abstract][Full Text] [Related]
4. Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.
Boullin DJ; Orr MW
Br J Clin Pharmacol; 1976 Oct; 3(5):929-33. PubMed ID: 973989
[TBL] [Abstract][Full Text] [Related]
5. The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.
Knox JM; Orr MW; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):261-3. PubMed ID: 6111334
[TBL] [Abstract][Full Text] [Related]
6. Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Clin Pharmacol; 1975 Feb; 2(1):37-9. PubMed ID: 791317
[TBL] [Abstract][Full Text] [Related]
7. Proceedings: Cellular biochemical pharmacology in monitoring drug therapy.
Grahame-Smith DG; Aronson JK; Boulin DJ; Orr MW
Arzneimittelforschung; 1976; 26(6):1256-7. PubMed ID: 989454
[No Abstract] [Full Text] [Related]
8. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
[TBL] [Abstract][Full Text] [Related]
9. Increased platelet aggregation in patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine.
Boullin DJ; Grimes RP
Br J Clin Pharmacol; 1976 Aug; 3(4):649-53. PubMed ID: 22216508
[TBL] [Abstract][Full Text] [Related]
10. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
Oppenheim B; Hefez A; Youdim MB
Prog Biochem Pharmacol; 1980; 16():119-32. PubMed ID: 7443729
[TBL] [Abstract][Full Text] [Related]
11. The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.
Orr MW; Boullin DJ
Br J Clin Pharmacol; 1976 Oct; 3(5):925-8. PubMed ID: 973988
[TBL] [Abstract][Full Text] [Related]
12. Platelet function after the administration of chlorpromazine to human subjects.
Warlow C; Ogston D; Douglas AS
Haemostasis; 1976; 5(1):21-6. PubMed ID: 1269995
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Pharmacol; 1975 Jan; 53(1):121-5. PubMed ID: 1125484
[TBL] [Abstract][Full Text] [Related]
14. [Effect of chlorpromazine, dipyridamole and verapamil on platelet aggregation on the arachidonic acid metabolism].
Zucchella M; Pacchiarini L; Grignani G
Boll Soc Ital Biol Sper; 1987 Dec; 63(12):1137-44. PubMed ID: 3135826
[No Abstract] [Full Text] [Related]
15. Serum tryptophan binding in chlorpromazine-treated chronic schizophrenics.
Bender DA; Bamji AN
J Neurochem; 1974 May; 22(5):805-9. PubMed ID: 4407100
[No Abstract] [Full Text] [Related]
16. [Comparative effect of chlorpromazine, imipramine and papaverine on the blood platelet function].
Bartel' V; Gluza E; Markvardt F
Farmakol Toksikol; 1976; 39(3):296-301. PubMed ID: 193725
[TBL] [Abstract][Full Text] [Related]
17. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.
Boullin DJ; Glenton PA
Br J Pharmacol; 1978 Apr; 62(4):537-42. PubMed ID: 26445
[TBL] [Abstract][Full Text] [Related]
18. Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current.
Prokopenko RA; Mogilevich SE; Luik AI; Naydyenova IY; Batrak GN; Hawryluk BR; Degtiar VY
Gen Physiol Biophys; 1995 Aug; 14(4):349-57. PubMed ID: 8720698
[TBL] [Abstract][Full Text] [Related]
19. Blunted serotonergic responsivity in neuroleptic-naïve patients at first-episode of schizophrenia.
Reddy R; Keshavan M; Yao JK
Schizophr Res; 2007 Feb; 90(1-3):81-5. PubMed ID: 17204398
[TBL] [Abstract][Full Text] [Related]
20. Role of chlorpromazine in maintaining timing behavior in chronic schizophrenics.
Angle HV
Psychopharmacologia; 1973 Jan; 28(2):185-94. PubMed ID: 4694626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
